Non Alcoholic Steatohepatitis (NASH) Market

Market Synopsis:

Global Non Alcoholic Steatohepatitis (NASH) Market is valued at USD 1,569 Million in 2021 and is projected to attain a value of USD 21,879 Million by 2028 at a CAGR of 60.4% during the forecast period, 2022–2028. Non Alcoholic Steatohepatitis (NASH) is a medical disorder in which the accumulation of fat around the liver causes inflammation and damage to the liver. It's a type of NAFLD (non-alcoholic fatty liver disease) that affects a lot of people (non-alcoholic fatty liver disease). Non Alcoholic Steatohepatitis (NASH) can worsen and lead to liver scarring, which can progress to cirrhosis. It has a resemblance to a type of liver condition induced by long-term alcohol addiction. It is, nevertheless, found in those who consume little or no alcohol.

Obesity, high triglycerides, metabolic syndrome, high cholesterol, insulin resistance, and type 2 diabetes are only a few of the major risk factors for NASH and liver injury. Obesity and diabetes are becoming more common in developed and developing economies as a result of sedentary lifestyles, higher calorie intake linked with processed food consumption, and alcoholism, all of which are anticipated to fuel the rise of the Non Alcoholic Steatohepatitis (NASH) market.

The recent outbreak of COVID-19 has prompted Non Alcoholic Steatohepatitis (NASH) solution vendors to respond fast in order to meet the growing need for high-quality virus protection services. COVID-19 has engulfed the whole healthcare ecosystem, from pharmaceutical corporations to medicine producers to COVID-19 vaccine developers to health insurance and hospitals, thanks to its rapid expansion. This will further escalate Non Alcoholic Steatohepatitis (NASH) Market.

High Prevalence of Hypertension

Hypertension affects around 26% of the world's population, with the prevalence expected to rise to 29% by the end of 2025. The increasing incidence of hypertension is causing a significant public health burden, with the majority of cases occurring in economically developing countries. Diabetes was directly responsible for nearly 1.6 million fatalities in 2016, according to the WHO, making it the seventh greatest cause of death in the same year. Aside from diabetes and hypertension, the incidence of dyslipidemia (high blood lipid) would open up attractive opportunities for the Non Alcoholic Steatohepatitis (NASH) sector.

No Approved Drugs

There are currently no licenced medications to treat Non Alcoholic Steatohepatitis (NASH) , although various businesses are working on developing new drugs using organic and inorganic methodologies. For example, on August 4, 2020, Merck & Co., located in the United States, signed a licencing agreement with Hanmi Pharmaceutical, based in Seoul, to commercialise efinopegdutide, a GLP-1/glucagon receptor dual agonist developed for the treatment of nonalcoholic steatohepatitis (NASH). Merck & Co. may pay the Korean pharmaceutical company about USD 800 million under a licencing arrangement for medications developed for NASH. Over the analysis period, higher investments in R&D and medication development, as well as an increased focus on growth strategies by industry companies, would produce favourable conditions for industry expansion.

Market Segmentation:

Global Non Alcoholic Steatohepatitis (NASH) Market is segmented on the basis of Drug Type into Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cencicriviroc and Others. Based on Sales Channel, the Non Alcoholic Steatohepatitis (NASH) market segmented into Hospital Pharmacy, Online Provider, Retail Pharmacy. Based on region, the Non Alcoholic Steatohepatitis (NASH) market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Non Alcoholic Steatohepatitis (NASH) Market

Over the forecast period, the Non Alcoholic Steatohepatitis (NASH) market in North America is expected to grow at a CAGR of 50%. According to recent estimates, the prevalence of NAFLD in the United States is over 25%, with Non Alcoholic Steatohepatitis (NASH) accounting for 3–8% of the total. Drugmakers will benefit from the rising prevalence of ailments in the region. The development of innovative medications for the treatment of Non Alcoholic Steatohepatitis (NASH) is being boosted by key regional manufacturers engaging in R&D operations.

Key Players:

Some of the players in the Non Alcoholic Steatohepatitis (NASH) market include Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc..

Non Alcoholic Steatohepatitis (NASH) Market is segmented as follows:

Non Alcoholic Steatohepatitis (NASH) Market is tabulated as follows: